Roche's Innovative Drug Engine ‘Firing On All Cylinders’
Pharma Head Used Q1 To Flag Catalysts, Early Projects
Roche’s Q1 update highlighted some key coming drug catalysts and early stage clinical efforts, including those for a potential COVID pill and for targeted cancer vaccines.
You may also be interested in...
Biosimilar erosion and slack drugs sales caused by the pandemic depressed Roche’s first quarter pharma revenue while its diagnostics unit saw sales soar on COVID testing.
Roche’s Phase III of tominersen in Huntington's disease has been stopped after an independent interim review, but with no new or emerging safety signals reported, analysts presume efficacy was the problem.
Positive pivotal results with Tecentriq in early post-surgery lung cancer should give Roche’s PD-L1 inhibitor pole position within its class for the blockbuster indication. But rivals are hot on its tail.